Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:59 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 937–960 of 4,175 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control comparison Clear all

Conditions: Knee Osteoarthritis
Interventions: Micronized DHACM 40 mg, Micronized DHACM 100 mg, Saline; Biological · Drug
Lead sponsor: MiMedx Group, Inc.; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 14
States / cities: La Mesa, California • Miami, Florida • The Villages, Florida + 9 more

Conditions: Otitis Media, Otitis Media Chronic, Otitis Media Effusion, Otitis Media Recurrent, Otitis Media in Children
Interventions: CLiKX® Tympanostomy Tube Delivery System; Device
Lead sponsor: ClinQure, Inc.; Network
Eligibility: 6 Months and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 4
States / cities: Louisville, Kentucky • Houston, Texas • Mesquite, Texas + 1 more

Conditions: Cardiac Arrest, Out-Of-Hospital
Interventions: CPR Training, CPR Manikin Type; Behavioral · Device
Lead sponsor: University of Nevada, Reno; Other
Eligibility: Not listed
Enrollment: 2,100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Reno, Nevada

Conditions: Rotator Cuff Tears
Interventions: Ortho-R/PRP; Drug
Lead sponsor: ChitogenX Inc; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 9
States / cities: Birmingham, Alabama • Tucson, Arizona • Fort Lauderdale, Florida + 6 more

Conditions: Mucociliary Clearance
Interventions: Mucinex 1200mg, Placebo; Drug
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 50 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Wound Care, Venous Ulcer Care, Wound Cleansing, Chronic Wound Care
Interventions: Prontosan wound irrigation solution; Device
Lead sponsor: Calvary Hospital, Bronx, NY; Other
Eligibility: 18 Years to 95 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Preterm Birth
Interventions: Screened Arm; Other
Lead sponsor: Christiana Care Health Services; Other
Eligibility: 18 Years and older · Female only
Enrollment: 1,873 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Parkinson's Disease, Idiopathic
Interventions: buntanetap/posiphen, Placebo; Drug
Lead sponsor: Annovis Bio Inc.; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 523 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 43
States / cities: Birmingham, Alabama • Sun City, Arizona • Fountain Valley, California + 35 more

Conditions: Muscle Damage
Interventions: cold water immersion, beta-hydroxy-beta-methylbutyrate free acid (HMB-FA), Placebo; Procedure · Dietary Supplement
Lead sponsor: Metabolic Technologies Inc.; Industry
Eligibility: 18 Years to 35 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Chronic Low Back Pain
Interventions: ABT-712, Placebo; Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 21 Years to 75 Years
Enrollment: 308 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 32
States / cities: Tempe, Arizona • Tucson, Arizona • Anaheim, California + 26 more

Conditions: Mammoplasty, Scarring, Scar, Breast Reconstruction
Interventions: Granexin® gel 100 μM, Granexin® gel 200 μM, Vehicle gel; Drug
Lead sponsor: Xequel Bio, Inc.; Other
Eligibility: 18 Years and older · Female only
Enrollment: 184 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2022
U.S. locations: 11
States / cities: Los Angeles, California • Pasadena, California • Doral, Florida + 8 more

Conditions: Infertility, Recurrent Pregnancy Loss
Interventions: PGD, PGD; Genetic · Procedure
Lead sponsor: Reprogenetics; Industry
Eligibility: 32 Years to 42 Years · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 4
States / cities: Beverly Hills, California • Highland Park, Illinois • Livingston, New Jersey + 1 more

Conditions: Lupus
Interventions: Coping skills and cognitive restructuring techniques, Educational training; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 12 Years to 18 Years · Female only
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Generalized Anxiety Disorder
Interventions: Not listed
Lead sponsor: Hartford Hospital; Other
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Multiple Myeloma
Interventions: Elranatamab, Standard of Care; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 633 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: BI 730357, Placebo to match BI 730357, Ciprofloxacin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 85 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Type 2 Diabetes
Interventions: Online Diabetes Self-Management Education and Support (DSMES) Program; Behavioral
Lead sponsor: Omada Health, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Metastatic Neuroendocrine Tumor
Interventions: Biospecimen Collection, Computed Tomography, Lutetium Lu 177 Dotatate, Magnetic Resonance Imaging, Triapine; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 94 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 25
States / cities: Duarte, California • Irvine, California • Orange, California + 19 more

Conditions: Neonatal Abstinence Syndrome
Interventions: Clonidine, Phenobarbital; Drug
Lead sponsor: Baystate Medical Center; Other
Eligibility: Up to 15 Days
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Springfield, Massachusetts

Conditions: Type 2 Diabetes
Interventions: INCB019602, Placebo, Metformin; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 22
States / cities: Phoenix, Arizona • Tucson, Arizona • Chula Vista, California + 19 more

Conditions: Dermatitis Atopic
Interventions: Amlitelimab, Placebo, Tdap vaccine, PPS vaccine; Drug · Biological
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 47
States / cities: Birmingham, Alabama • Scottsdale, Arizona • Anaheim, California + 40 more

Conditions: Type 2 Diabetes Mellitus
Interventions: HOE901-U300 (new formulation of insulin glargine), Lantus (insulin glargine); Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 878 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 117
States / cities: Montgomery, Alabama • Chandler, Arizona • Mesa, Arizona + 93 more

Conditions: Neck Pain
Interventions: Supine Thoracic Spine Manipulation, Prone Thoracic Spine Manipulation; Other
Lead sponsor: A.T. Still University of Health Sciences; Other
Eligibility: 22 Years to 50 Years
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Mesa, Arizona

Conditions: Chronic Hepatitis B
Interventions: TDF, ADV, TDF placebo, ADV placebo, FTC/TDF; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 69 Years
Enrollment: 382 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2016
U.S. locations: 17
States / cities: La Jolla, California • Pasadena, California • San Diego, California + 12 more

Search by objective public record fields.

Phase 2B Micronized DHACM vs. Saline in the Treatment of Knee Osteoarthritis

CLIKX® Tympanostomy Tube Delivery System for the Placement of Tympanostomy Tubes

Gathering Evidence on Best Practices for Lay Rescuer CPR Training

Ortho-R® for Rotator Cuff Repair Compared With Standard of Care Rotator Cuff Repair Without Ortho-R®

Evaluating the Effect of Mucinex® 1200 mg on Mucociliary and Cough Clearance From the Human Lung

Effect of Prontosan Wound Irrigation Solution on Venous Ulcers

Serum Assessment of Preterm Birth Outcomes Compared to Historical Controls: AVERT PRETERM TRIAL

A Double-blind Study to Investigate Efficacy and Safety of Buntanetap Compared With Placebo in Participants With Early PD

Comparison of Pre-exercise Beta-hydroxy-beta-methylbutyrate Free Acid (HMB-FA) and Cold Water Therapy for the Attenuation of Muscle Damage and Soreness

Study to Evaluate the Safety and Efficacy of ABT-712 in Subjects With Moderate to Severe Chronic Low Back Pain (CLBP)

A Study of Granexin® Gel for the Reduction of Scar Formation in Surgical Wounds Following Bilateral Anchor Incision Breast Surgery

Preimplantation Genetic Diagnosis Using Blastocyst Biopsy and Array CGH

Improving Quality of Life for African American Female Adolescents With Lupus

Locating Regions of Interest in Generalized Anxiety Disorder Using Function Magnetic Resonance Imaging (fMRI)

A Study to Compare the Effects of Elranatamab (PF 06863135) Versus Standard of Care (SOC) in Patients With Multiple Myeloma (MM) in Germany and US

Evaluation of Photosafety of BI 730357 Compared to Placebo and the Known Photosensitizing Agent Ciprofloxacin

Impact of a Digital Self-Management Program on A1C for Individuals With Type 2 Diabetes

Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors

Clonidine for Neonatal Abstinence Syndrome Study

Evaluate the Safety and Tolerability of INCB019602 When Administered With Metformin in Patients With Type 2 Diabetes

A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo

Comparison of a New Formulation of Insulin Glargine With Lantus in Patients With Type 2 Diabetes on Non-insulin Antidiabetic Therapy

Comparison of Two Thoracic Manipulation Techniques to Improve Neck Pain

A Study to Compare Tenofovir Disoproxil Fumarate Versus Adefovir Dipivoxil for the Treatment of HBeAg-Negative Chronic Hepatitis B